Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDE574
- Development stage
- Phase 1
- Lead developer
- IDEAYA Biosciences
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
IDE574 is a first-in-class dual inhibitor of the histone lysine acetyltransferases KAT6 and KAT7, being developed by IDEAYA Biosciences as an antineoplastic agent. The drug targets the KAT6A, KAT6B, and KAT7 proteins to inhibit their activity. These enzymes are involved in chromatin remodeling and gene expression regulation through acetylation of histone proteins. By inhibiting these targets, IDE574 aims to disrupt oncogenic transcriptional programs in cancer cells. As of May 2025, it is classified as a new molecular entity and is in preclinical development for solid tumors[1][3].
02
Targets
KAT6A (Lysine acetyltransferase 6A)KAT6B (Histone acetyltransferase KAT6B)KAT7 (Lysine acetyltransferase 7)
Beyond the preview
Go deeper on IDE574.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDE574.